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ABSTRACT 
Myotonic dystrophy type 1 (DM1) is an autosomal dominant inherited disorder, caused by expansion 
of a germline and somatically unstable CTG repeat in the DMPK gene. Previously, CTG repeat length 
at birth has been correlated to patient age at symptom onset. Attempts to correlate CTG repeat length 
with progressive DM1 phenotypes, such as muscle power, have proven difficult. To better correlate 
genotype with progressive phenotypes, we have measured CTG repeat tract length and screened for 
interrupting variant repeats in 192 study participants from a well-characterized Canadian cohort. We 
have assessed genotype-phenotype correlations with nine progressive measures of skeletal muscle 
power and respiratory function. We have built statistical models which include confounding factors 
such as sex, age, height and weight to further explain variation in muscle power. Our analysis reveals 
a strong correlation between DM1 genotype and respiratory function and skeletal muscle power, as 
part of a complex model which includes additional modulators such as sex, age, height, weight, and 
the presence or absence of interrupting variant repeats. Distal skeletal muscle measurements, such as 
hand pinch and grip strength, show the strongest correlation with disease genotype. Detailed analysis 
of CTG repeat length, and incorporation of confounding factors, greatly improves the predictive 
ability of these models. They reveal a greater genetic influence on individual progressive phenotypes 
than on age at symptom onset, and for clinical trials will help optimise stratification and explain 
patient variability. They will also help practitioners prioritise assessment of the muscular power 
measurements which correlate best with disease severity.  
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INTRODUCTION 
Myotonic dystrophy type 1 (DM1 [MIM: 160900]) is an autosomal dominant inherited disorder and is 
the commonest form of muscular dystrophy in adults (1, 2). The age of symptom onset varies 
massively, from birth in congenital cases, to old age in the mildest form of DM1. The characteristic 
symptoms are distal skeletal muscle weakness and myotonia, but additional symptoms exhibited by 
each patient are highly variable, and include heart conduction defects, cataracts, testicular atrophy and 
gastrointestinal disorders (1).  
The genetic basis of DM1 is the expansion of an unstable CTG repeat in the 3’-UTR of the DMPK 
gene (HGNC:2933) (3-5). In the general population, the triplet repeat is polymorphic, ranging from 5 
to ~35 repeats. In DM1 patients, disease severity correlates with repeat size at birth, from 50+ CTG 
repeats in mild cases, to 1000+ CTG repeats in congenitally affected children (3-8). Once in the 
disease range, the CTG tract becomes highly unstable in the germline and frequently expands from 
one generation to the next (9-12). This results in anticipation; an increase in symptom severity and a 
decrease in age at onset of 20 to 30 years per generation (13). In addition to germinal instability, the 
expanded CTG tract is highly unstable in the soma, in a process that is age- and allele-length 
dependent, and expansion biased (14-16). The rate of expansion is highly variable among tissues (17-
20), which likely contributes towards the tissue-specific symptoms and progressive nature of the 
condition. Patients with a CTG tract which expands faster than expected, develop symptoms earlier 
than expected, showing a direct correlation between somatic instability and disease severity (21, 22).  
Somatic instability has confounded attempts to measure the expanded CTG allele length in DM1 
patients. The most accurate method for assessing somatic instability is small pool-PCR (SP-PCR). SP-
PCR (23) allows us to estimate the progenitor allele length (ePAL) which a patient was born with, in 
addition to the modal allele size at the time of DNA sampling (16, 22). ePAL is the best predictor of 
age at symptom onset, and corrects the confounding effects of age at sampling. Although the majority 
of DM1 patients inherit a pure CTG expansion at the DMPK locus, a proportion of patients have 
variant repeats – such as CCG or CGG – in the repeat tract (24, 25). These variant repeats reduce both 
germline and somatic instability (25), and appear to be associated with delayed age at symptom onset 
(24-27). 
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As age at symptom onset is subjective and unlikely to be an outcome measure in clinical trials in the 
short-to-medium term, it is essential to identify objective phenotypes with a causal genetic 
relationship, and also to establish whether the presence of variant repeats effects the rate-of-change of 
progressive phenotypes. Currently there is little conclusive data correlating CTG repeat number with 
progressive clinical phenotypes such as muscle power (28, 29), likely due to failure to account for 
somatic mosaicism and the presence of variant repeats, alongside other complex interactions such as 
sex and age. Another factor is the sampling bias often found in DM1 studies, which comprise of a mix 
of older, milder patients with smaller CTG alleles, and younger, more severe patients born with larger 
CTG alleles. Analysis therefore requires dissociation of age-dependent phenotypic decline, from 
disease-dependent phenotypic decline, which is difficult in small cohorts. Identification of a set of 
easily-measured phenotypes, which correlate strongly with genotype, would also be useful for 
practitioners who need to routinely track disease progression. 
The Saguenay-Lac-Saint-Jean region of Canada is a population of French-Canadian origin and has the 
highest incidence of DM1 worldwide, with a frequency of ~1/630 (30), from a common DM1 founder 
who settled ~14 generations ago (31, 32). The population is the subject of an ongoing longitudinal 
study to find the determinants of disability and quality of life in DM1. From 2002 to 2004, 200 DM1 
patients were recruited into an extensive study which assessed muscle, pulmonary, cardiac, metabolic, 
endocrine and neurocognitive function, as well as social participation. The medical history of each 
participant was reviewed, and when possible an age at DM1 symptom onset was determined. Blood 
DNA was collected during the study, providing an opportunity to determine ePAL and the modal 
repeat expansion from birth. 
We have sought to correlate CTG repeat length with nine objective measures of respiratory function 
and skeletal muscle power, to assess their correlation with progressive phenotypes which could be 
assessed during clinical trials, and by practitioners. We hypothesise that these are complex 
phenotypes, strongly mediated by the same sex and age factors that modulate muscle power in the 
general population, and complicated further by the impact of myotonic dystrophy type 1. 
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RESULTS 
Estimation of progenitor and modal allele length 
Blood DNA samples were available for 192 of the 200 Saguenay study participants. We used SP-PCR 
(16) to estimate the progenitor allele length (ePAL) (22) and modal allele length for each participant 
(Figure 1A). An expanded CTG repeat allele was identified in 186 participants using our standard SP-
PCR protocol. In an additional five participants, an expanded CTG repeat was identified after the 
addition of 10% DMSO to the PCR. A requirement for DMSO is usually indicative of the presence of 
a GC-rich variant repeat interrupting the CTG tract (25). In one individual we were unable to amplify 
an expanded allele, although it was possible to amplify a single non-expanded allele, suggesting the 
blood DNA was of good quality. Again, this is usually indicative of a large number of GC-rich variant 
repeats (CCG or CGG) in the CTG tract. In the 191 participants successfully genotyped, the ePAL 
ranged from 48 to 1060 CTG repeats, and the modal allele ranged from 52 to 1470 repeats. 
 
Identification of AciI sensitive variants in the expanded allele 
Non-CTG variants within the expanded allele can have a significant effect on both the somatic and 
germline stability of the repeat tract (25). We used SP-PCR to amplify the CTG repeat, and tested for 
the presence of the most common repeats – CCG and CGG – by post-PCR digestion with AciI, which 
cuts in the presence of CCG or CGG (Figure 1B)(25). We identified variants in the repeat tract of 17 
out of 191 expanded alleles (8.9%). This included all of the samples which required the addition of 
DMSO to facilitate SP-PCR. No AciI sensitive variants were identified in the non–disease causing 
allele of the participants. 
 
Correlation of ePAL and age at symptom onset in the cohort 
Patient age at onset of symptoms was available for 147 participants in the Saguenay study. We used 
linear regression modelling to investigate the relationship between repeat length at birth, and the age 
at which symptoms become apparent (Figure 2A). As expected, ePAL was a major modifier of age at 
symptom onset (Table 1, Model 1a, r2 = 0.217, p <0.001) (22, 33). Additionally, we tested whether the 
presence/absence of AciI sensitive sites further modified age at onset. The presence of AciI sensitive 
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sites was significantly associated (p = 0.011) with a later age at onset (Model 1b, r2 = 0.247, p 
<0.001). We further tested whether sex had an effect on genotype-phenotype correlations, and found 
male patients to have a later age at symptom onset (Model 1c, r2 = 0.263, p <0.001), although the 
effect was small and only marginally significant (p = 0.05). This is likely due to skewing within the 
cohort, as age at symptom onset data is available for a larger proportion of males with a small ePAL 
(< 100 rpts) than females. 
 
Somatic instability in the Saguenay cohort 
Somatic instability can be defined as the change in the modal CTG repeat number between birth and 
the time at which the DNA is sampled. In this study, we have quantified somatic instability as the 
difference between the ePAL (22) and modal repeat number during the study. In the Saguenay cohort 
somatic instability is strongly correlated with ePAL and the presence/absence of AciI sensitivity in the 
repeat tract (Model 2b, r2 = 0.658, p <0.001). The model was further improved by including age at 
sampling (p <0.001) as an additional variable (Model 2c, r2 = 0.684, p <0.001). Linear regression of 
repeat tract AciI sensitive/insensitive subgroups again showed that somatic instability was lower in 
AciI sensitive participants (Figure 2B, n = 16, r2 = 0.525, p = 0.001), than insensitive participants (n = 
175, r2 = 0.652, p <0.001). Including the sex of the participant as a variable did not improve the 
regression model. 
 
Genotype-phenotype correlations in the Saguenay cohort 
Nine clinical measures of skeletal muscle power and respiratory function were available for the 
Saguenay cohort – maximal inspiratory pressure (MIP), maximal expiratory pressure (MEP), forced 
vital capacity (FVC), peak expiratory flow (PEF), and power measurements for grip, pinch, shoulder 
abductors, knee extensors, and ankle dorsiflexors. ePAL correlated significantly with seven of the 
nine measures without inclusion of any additional variables (Figure 3, r2 ranged from 0.071 to 0.443). 
As the cohort is comprised of both sexes, and a wide range of ages, we would expect that sex, age at 
sampling, height and weight may also contribute to phenotypes, and included them as parameters in 
the linear regression model. ePAL was a significant contributor to all nine respiratory function and 
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muscular power phenotypes when combined with age and/or sex (Table 2, Supplementary Figure 1), 
and for six of the phenotypes was the strongest contributor to the model (Table 2, see β values). 
Repeat tract AciI sensitivity was significant for six of the phenotypes, including all five measures of 
skeletal muscle power. The modal CTG repeat length during the study was significantly correlated 
with eight of the nine phenotypes without correction for age or sex (Figure 4, r2 ranged from 0.049 to 
0.505). When age and/or sex were added to the model, it became a significant modulator of all nine 
models, and was the most significant contributor to six phenotypes (Table 3, see β values). As with 
ePAL, CTG repeat tract AciI sensitivity appeared to be most important for the measures of skeletal 
muscle power.  
 
DISCUSSION 
The Saguenay-Lac-Saint-Jean clinical cohort is phenotypically well characterised, and genetic 
analysis has allowed us to correlate these phenotypes with DM1 genotype. By understanding the 
contribution of the DMPK CTG repeat to clinical phenotypes, we can both improve prognostic 
accuracy and identify further genetic factors which contribute to disease severity. Most importantly, 
we can also identify progressive symptoms which correlate robustly with the CTG expansion and can 
be used as an objective measure of disease severity in clinical trials. 
In the Saguenay cohort, 8.9% of participants have AciI sensitive sites in the CTG repeat region, which 
significantly decrease somatic instability and increase age at symptom onset (Table 1, Models 1b and 
2c). This is higher than the 3 to 5% previously noted in studies of Serbian (34), French (25) and 
Czech (24) DM1 patients. As the Saguenay cohort share a relatively recent ancestor, and there were 
no AciI sites found in the smaller non-disease causing alleles, this suggests a high frequency of de 
novo mutations in the CTG tract subsequent to expansion into the disease range. These data show that 
the presence of AciI sensitive variant repeats affects genotype/phenotype correlations, including 
progressive phenotypes likely to be measured in clinical trials. The data we present here indicate that 
in addition to having a greater absolute age at onset, variant repeat patients are less severely affected 
than would be expected at a given time-point. It thus seems reasonable to assume that such patients 
will also have a slower rate of decline, although additional longitudinal data is required to verify this. 
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Thus, until we understand better their role, we would suggest that for clinical trials, variant repeat 
patients are either excluded, or that any control/treated groups are matched to contain a similar 
number of variant repeat patients, to minimise the likelihood of skewing the rate of decline in either 
group. 
ePAL and repeat tract AciI sensitivity are the most significant modifiers of age at symptom onset in 
the Saguenay study (r2 = 0.247, Model 1b). The proportion of age at onset explained by ePAL and 
AciI sensitivity is lower than the 64% found in a previous study (22). This is likely due to having few 
late onset patients and no congenital/juvenile onset patients in the sampled Saguenay cohort. 
Although it is important to understand the correlation between genotype and age at symptom onset 
within the Saguenay cohort, for clinicians, objective measures of progressive phenotypes will be more 
informative. 
The phenotypes affected by DM1, such as skeletal muscle power and respiratory function, can be 
influenced by many lifestyle and genetic parameters. Therefore, it is important to understand how 
much of the variation in these phenotypes can be attributed to the causative DMPK CTG repeat in 
DM1 patients. By identifying phenotypes strongly associated with the genetic cause of disease, and 
less influenced by confounding factors, we can rationalise the best measures of disease status. Most 
crucially, this will identify progressive phenotypes that can be used as measures of symptom 
improvement or worsening during clinical trials and by practitioners. Although there have been some 
promising studies (35), CTG length hasn’t always correlated consistently with progressive phenotypes 
such as muscle maximal contraction and relaxation time (36, 37). This is likely due to heterogeneity 
across tissues and small study size (28, 29), as well as sampling biases and the progressive nature of 
both CTG expansion and symptom severity. Hogrel et al noted a correlation between modal CTG 
repeat length and myotonia and grip strength, in a larger study of 144 patients (38). Although they 
considered the relationship not to be clinically meaningful, they noted that the study did not 
incorporate the relationship between phenotype and somatic instability or variant repeats, which may 
have improved their model. Determining CTG repeat size by SP-PCR, rather than restriction digest of 
genomic DNA, greatly improves accuracy, as restriction digest of genomic DNA does not separate 
larger alleles sufficiently to allow accurate sizing on a gel. Large fragments can have a migration 
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difference of a few millimetres, but repeat size difference of hundreds of CTGs, resulting in imprecise 
estimation. 
In this study, we analysed the genotype-phenotype correlation between ePAL and modal CTG allele 
length and nine common measures of respiratory function and skeletal muscle power. We also 
attempted to improve these models by including basic descriptors such as age, sex, height, and 
weight. For seven of the nine measures, ePAL was a significant modifier without correction for age, 
sex, height, weight or other genetic factors (Figure 3). This is perhaps the most striking in the more 
distal muscle measurements - grip strength (r2 = 0.443), pinch strength (r2 = 0.419) and ankle 
dorsiflexor strength (r2 = 0.202). As expected, the two skeletal muscle measurements for which ePAL 
was not individually significant are in more proximal muscle groups – knee extensor and shoulder 
abductor, which usually weaken later, if at all, in the disease. Nonetheless, when shoulder and knee 
strength are adjusted for sex, age, height, weight and AciI sensitivity, ePAL was a significant modifier 
of both phenotypes (Supplementary Figures 1G and 1H). This confirms that these basic descriptors 
are key contributors to muscle power phenotypes, and must be factored during analysis. All five 
skeletal muscle phenotypes were improved by adding CTG repeat AciI sensitivity to the model, 
suggesting that the stabilising effect of AciI sensitive sequences is being translated in to a significant 
decrease in the severity of progressive symptoms (Table 2). 
The modal repeat length during the study correlates significantly with eight of the nine phenotypes 
without correction for age or sex (Figure 4). Like ePAL, this is most robust in the more distal muscle 
measurements – grip strength (r2 = 0.505), pinch strength (r2 = 0.504) and ankle dorsiflexor strength 
(r2 = 0.281). Modal allele length was a predictor of all nine phenotypes when age and sex were added 
to the model, and alongside age, was the only descriptor which contributed significantly to every 
phenotype (Table 3). Again, the combination of sex, age, height and weight measurements which add 
significantly to the regression was unique to every phenotype. The r2 for each model was marginally 
higher when using the modal CTG repeat length than the ePAL. Modal repeat length is nominally a 
measure of ePAL combined with individual dynamics of somatic mutation, and in this study, captures 
somatic instability better than ePAL factored with age at sampling. Accurate estimation of repeat 
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length using SP-PCR is the most important factor for good correlation, no matter whether ePAL or 
modal repeat length is used. 
These data suggest that objective phenotypes such as pinch strength could be utilised as outcome 
measurements in clinical trials. Genotype correlates better with pinch strength than age at symptom 
onset, even without the inclusion of mild or congenital DM1 patients. In a clinical trial we would 
expect that symptom improvement would likelier be captured using pinch strength, for which DM1 
genotype explains ~50% of muscle power, than other phenotypes such as FVC, where DM1 genotype 
only explains ~18% of respiratory capacity (Figures 4F and 4C), and factors such as age and sex have 
a greater impact. All of the Saguenay cohort registered a pinch strength > 0 kg, allowing for 
measurement of both muscle worsening and improvement over time. Grip strength has a similarly 
strong correlation with genotype, but numerous patients registered no grip strength (0 kg), making it 
impossible to measure worsening of the phenotype. Muscle power measurements such as grip and 
pinch strength are also relatively simple and inexpensive to assess annually by a clinician, and could 
potentially be useful in the development of clinical biomarkers. 
The models constructed in this study have all utilised CTG allele length as determined from blood 
DNA. Outcome measurements which correlate with repeat length in blood DNA, such as these, would 
be preferable for clinical trials as it negates the need for muscle biopsy samples. This analysis also 
factors sex, age, height and weight as individual factors in each model, rather than expressing 
phenotypes as a percentage of a predicted value for a ‘healthy’ individual. This allows us to perform 
analysis on clinical phenotypes for which extensive ‘normative’ data is not available, yet still account 
for natural variation in age, sex, height and weight. It also prevents the masking of interactions which 
may be specific to the myotonic dystrophy type 1 population, such as the effect of age on both 
somatic instability and muscle power. 
In conclusion, by factoring CTG allele length and the absence/presence of variant repeats in the CTG 
tract with basic descriptors such as sex and age, we can correlate DM1 genotype with progressive 
measures of phenotype which could be measured during clinical trials, or by practitioners with DM1 
patients. Recent studies suggest that drug mechanisms with genetic support are twice as likely to be 
approved during clinical trials (39), as it ensures a causal link between drug target and disease. 
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Similarly, we would suggest that outcome measures which are best correlated with DM1 genotype are 
more likely to be useful during clinical studies, as they reflect a quantifiable causal relationship. 
 
MATERIALS AND METHODS 
Participants 
From 2002 to 2004, 200 patients of the Neuromuscular Clinic of the Centre de Santé et des services 
sociaux de Jonquière (Québec, Canada) were recruited into DM027, a longitudinal study aimed at 
finding the determinants of disability, social participation and quality of life in DM1. The study 
focused on adult and late onset DM1 patients, and those with congenital or childhood DM1 were 
excluded from participating. 
 
Ethical standards and informed consent 
This study was approved by the appropriate ethics committee (Ethics Review Board of the CIUSSS 
du Saguenay–Lac-St-Jean (Quebec, Canada)) and has been performed in accordance with the ethical 
standards laid down in the 1964 Declaration of Helsinki and its later amendments. All participants 
gave their informed consent before their inclusion in the study. 
 
Clinical measurements 
Age at symptom onset was estimated by an experienced DM1 clinician using a combination of patient 
interviews and available medical records. The symptoms first experienced by a patient are variable, 
and in this study it was patient age at the first recognisable DM1 symptom, such as cataracts or 
weakness of the hand muscles, that was used. For 45 of the 192 Saguenay patients it was not possible 
to confidently estimate an age at symptom onset, and as such they were excluded from the age at 
symptom onset analysis. 
Maximal inspiratory and expiratory pressure, forced vital capacity and peak expiratory flow were 
measured by a respiratory therapist at the Jonquiere Hospital following a standardized protocol. 
Values used during analysis were uncorrected for age, height, or sex, which were considered as 
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independent variables in the multiple linear regression. Shoulder abductor, knee extensor and ankle 
dorsiflexor strength were measured twice for both left and right limbs, using a Microfet-2 (Hoggan 
Health Industries, USA), as previously described (40). The participant’s position was standardized for 
each muscle group before measurement. The maximal isometric torque was calculated by multiplying 
strength units (Newton) by the length of the corresponding lever (meters). The mean of the four 
values was calculated and used in the linear regression analysis. Grip strength was measured using a 
Jamar dynamometer (Asimow Engineering Co., USA), and lateral pinch strength using an A B & L 
Pinch Gauge (Fabrication Enterprises Inc, USA), following the protocols recommended by the 
American Society of Hand Therapists(41). Each standardized test was performed in triplicate, and the 
mean value used for linear regression. The cohort minimum, maximum and mean values for each 
measurement can be found in Supplementary Table 1. 
 
Small pool PCR amplification of DM1 alleles 
For each patient, a blood sample was taken at entry into the DM027 study, and genomic DNA 
extracted using the Gentra Puregene Blood Kit (Qiagen, USA). PCR amplification of the DMPK CTG 
repeat was carried out using the flanking primers DM-C and DM-DR as previously described (16). 
The PCR buffer was Custom PCR Master Mix-No Taq (Thermo Scientific #SM-0005) supplemented 
with 69 mM 2-mercaptoethanol. Taq polymerase (Sigma-Aldrich UK) was used at 1 unit per 10 µl. 
Where required, reactions were supplemented with 10% DMSO (Sigma-Aldrich UK) and the 
annealing temperature reduced from 68°C to 63.5°C. PCR products were digested with AciI (42) in 
accordance with the manufacturer’s instructions (New England Biolabs UK Ltd). 
 
Small pool Southern blot hybridization 
PCR amplified DM1 alleles were resolved on 1% agarose gels in 0.5X TBE, blotted, and hybridized 
as described (16). Molecular weight marker (Invitrogen 1 kb+ ladder, Thermo Fisher Scientific UK) 
and DNA probes were labelled using α-32P-dCTP (Perkin Elmer UK) and the Invitrogen Random 
Primers DNA labelling system (Thermo Fisher Scientific UK). The CTG probe was amplified using 
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flanking primers DM-C and DM-DR and a DM1 patient with 56 CTG repeats. After autoradiography, 
blot images were scanned, then ePAL and modal allele lengths were estimated from the lower 
boundary (16) and the densest part of the expanded allele distribution (22) respectively. Allele length 
was estimated by comparison to the 1kb+ ladder, using CLIQS 1D gel analysis software (TotalLabs 
UK).  
 
Statistical analysis 
Linear regression and multiple linear regression were undertaken in IBM SPSS statistics version 22 
(IBM, USA). ‘Stepwise’ regression was used, where all variables were considered for a model, and 
retained if they were significant coefficients (probability of ‘F’, entry < 0.1). Where variables were 
non-significant for a model, the β and significance are noted for reference. The β value is the absolute 
standardized coefficient, and represents the contribution of each variable to the model. The greater the 
β value associated with a variable (whether positive or negative), the greater its contribution to the 
model. Adjusted r2 was used to account for the number of predictors in the model, and where r2 values 
are reported it is the adjusted r2. A model was considered significant if p < 0.05. 
 
Data availability policy 
The datasets generated and/or analysed during this study are not currently publicly available because 
of the risk of patient de-identification, but are available for research upon reasonable request. The 
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available from Darren Monckton and Gayle Overend. 
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LEGENDS TO FIGURES: 
 
Figure 1. Estimation of the progenitor allele and modal allele and detection of AciI sensitive 
variant repeats in blood DNA. Shown are representative small pool PCR analyses of CTG repeat 
length at the DMPK locus in blood DNA. The approximate number of CTG repeats is shown on the 
left. A) The position of the estimated progenitor allele (ePAL) for each of four individuals is indicated 
by the lower white dashed line. The modal allele length at sampling is indicated by the upper white 
dashed line. For each sample four replicate PCRs were performed with ~ 300 pg genomic DNA. 
B) For both participants, three replicate PCRs were performed and digested with AciI (+) or left 
undigested (-) in a modified SP-PCR. Participant ID95 does not contain AciI sensitive sites within the 
expanded repeat, whereas participant ID106 does, as evidenced by the downward shift in band size. 
 
 
Figure 2. The estimated progenitor allele is the major modifier of age at symptom onset and 
somatic instability in DM1. A) The graph shows the relationship between ePAL and age at symptom 
onset (n = 146) in the Saguenay cohort. The solid line shows the regression line for all patients, using 
a logarithmic model (Table 1, Model 1a). The solid triangles denote patients with an AciI sensitive 
CTG repeat tract. B) The graph shows the relationship between ePAL and somatic instability during 
the study in CTG repeat AciI sensitive (solid triangles, n = 16) and CTG repeat AciI insensitive 
(diamonds, n = 175) participants. The lines show the regression line in AciI sensitive (broken line) 
and insensitive (solid line) subgroups, using a logarithmic model. 
 
 
Figure 3. The estimated progenitor allele length is a modifier of four measures of respiratory 
function and three measures of skeletal muscle power. The graphs show the relationship between 
ePAL and A) MIP, B) MEP, C) FVC, D) PEF, E) grip, F) pinch, G) shoulder, H) knee and I) ankle 
dorsiflexor strength, uncorrected for age, sex, height or weight. The solid line shows the logarithmic 
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regression line for the cohort, r2 and p values are for phenotype = log(ePAL). Solid black triangles 
represent patients with an AciI sensitive CTG repeat tract. 
 
  
Figure 4. The modal allele length is a modifier of four measures of respiratory function and four 
measures of skeletal muscle power. The graphs show the relationship between modal allele length 
and A) MIP, B) MEP, C) FVC, D) PEF, E) grip, F) pinch, G) shoulder, H) knee and I) ankle 
dorsiflexor strength, uncorrected for age, sex, height or weight. The solid line shows the logarithmic 
regression line for the cohort, r2 and p values are for phenotype = log(modal). Solid black triangles 
represent patients with an AciI sensitive CTG repeat tract. 
 
 
Supplementary Figure 1. Correlation between the progenitor allele and nine measures of 
respiratory function and skeletal muscle power is improved after factoring sex, age, height, 
weight and AciI sensitivity. The graphs show A) MIP (adjusted for age and sex), B) MEP (adjusted 
for sex), C) FVC (adjusted for height, weight, age and AciI sensitivity), D) PEF (adjusted for height 
and weight), E) grip (adjusted for AciI sensitivity and sex), F) pinch (adjusted for AciI sensitivity and 
sex), G) shoulder (adjusted for sex and weight), H) knee (adjusted for sex, AciI sensitivity, weight and 
age) and I) ankle dorsiflexor strength (adjusted for sex), plotted against ePAL, and the corresponding 
r2 and p-values. 
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TABLES: 
 
Table 1. Linear regression models for age at symptom onset and somatic instability. The models include age at symptom onset (age at onset), ePAL 
(ePAL), AciI sensitivity in the repeat tract (AciI), sex (sex) and somatic instability between birth and study sampling (somatic instability).  
 
Model adjusted r2 p Parameter  Beta  p 
1a) age at onset = log(ePAL) 0.217 <0.001 log(ePAL) - 0.472  
1b) age at onset = log(ePAL) + AciI 0.247 <0.001 log(ePAL) - 0.470 < 0.001 
   AciI  0.189  0.011 
1c) age at onset = log(ePAL) + AciI + sex 0.263 <0.001 log(ePAL) - 0.473 < 0.001 
   AciI  0.195  0.008 
   sex  0.144  0.050 
2a) somatic instability = log(ePAL) 0.614 <0.001   0.785  
2b) somatic instability = log(ePAL) + AciI 0.658 <0.001 log(ePAL  0.794 < 0.001 
   AciI - 0.214 < 0.001 
2c) somatic instability = log(ePAL) + AciI + age  0.684 <0.001 log(ePAL)  0.851 < 0.001 
   AciI - 0.208 < 0.001 
   age  0.174 < 0.001 
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Table 2. Linear regression of nine respiratory function and skeletal muscle measures against sex, age, height, weight, ePAL and AciI sensitivity. The 
table shows the adjusted r2 and p value for each model, and the standardized contribution (β) and significance (p value) of each individual component of the 
model. The strongest contributor to each model (as determined from the standardized β) is shown in bold font. Only parameters considered significant 
(marked with an *) were included in the adjusted r2. Also shown is the number of participants (n) for which each phenotype measure was available. 
 
  MIP  MEP  FVC  PEF  grip  pinch  shoulder  knee  ankle 
sex 
β  0.198  0.238  0.206  0.217  0.121  0.222  0.627  0.496  0.221 
p value  0.008*  0.001  0.006*  0.034*  0.112 < 0.001* < 0.001* < 0.001*  0.008* 
age 
β - 0.426 - 0.198 - 0.333 - 0.337 - 0.105 - 0.192 - 0.119 - 0.314 - 0.237 
p value < 0.001*  0.006* < 0.001* < 0.001*  0.057*  0.001*  0.072  0.001*  0.011* 
height 
β  0.071 - 0.013  0.465  0.285  0.161  0.045  0.145  0.000  0.056 
p value  0.503  0.903 < 0.001*  0.006*  0.002*  0.546  0.107  0.997  0.648 
weight 
β  0.041  0.129 - 0.246 - 0.017  0.006  0.080  0.321  0.245  0.067 
p value  0.595  0.071* < 0.001*  0.831  0.918  0.135 < 0.001*  0.004*  0.451 
log(ePAL) 
β - 0.387 - 0.590 - 0.468 - 0.485 - 0.718 - 0.724 - 0.271 - 0.283 - 0.580 
p value < 0.001* < 0.001* < 0.001* < 0.001* < 0.001* < 0.001* < 0.001*  0.002* < 0.001* 
AciI sensitivity 
β - 0.053 - 0.057  0.125 - 0.066  0.116  0.217  0.173  0.226  0.264 
p value  0.471  0.414  0.015*  0.364  0.002*  0.001*  0.004*  0.004*  0.002* 
adjusted r2  0.244  0.347  0.586  0.376  0.495  0.522  0.655  0.419  0.317 
significance (p value) < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 
participants (n)  144  142  166  125  189  188  106  105  106 
 
 23 
Table 3. Linear regression of nine respiratory function and skeletal muscle measures against sex, age, height, weight, modal allele length and AciI 
sensitivity. The table shows the adjusted r2 and p value for each model, and the contribution (β) and significance (p value) of each individual component of 
the model. The strongest contributor to each model (as determined from the standardized β) is shown in bold font. Only components considered significant 
(marked with an *) were included in the adjusted r2. 
 
  MIP  MEP  FVC  PEF  grip  pinch  shoulder  knee  ankle 
sex 
β  0.189  0.223  0.200  0.215  0.099  0.174  0.511  0.478  0.191 
p value  0.010*  0.002*  0.007*  0.037*  0.175  0.001* < 0.001* < 0.001*  0.017* 
age 
β - 0.423 - 0.192 - 0.340 - 0.336 - 0.120 - 0.199 - 0.111 - 0.330 - 0.234 
p value < 0.001*  0.007* < 0.001* < 0.001*  0.025* < 0.001*  0.084* < 0.001*  0.009* 
height 
β  0.045 - 0.056  0.467  0.260  0.136  0.010  0.149  0.014  0.052 
p value  0.671  0.582 < 0.001*  0.011*  0.007*  0.896  0.094*  0.901  0.664 
weight 
β  0.039  0.129 - 0.237 - 0.014 - 0.003  0.088  0.299  0.266  0.079 
p value  0.607  0.066* < 0.001*  0.863  0.952  0.084* < 0.001*  0.001*  0.365 
log(modal) 
β - 0.401 - 0.611 - 0.489 - 0.477 - 0.757 - 0.782 - 0.312 - 0.348 - 0.634 
p value < 0.001* < 0.001* < 0.001* < 0.001* < 0.001* < 0.001* < 0.001* < 0.001* < 0.001* 
AciI sensitivity 
β - 0.083 - 0.104  0.086 - 0.106  0.082  0.125  0.124  0.199  0.145 
p value  0.257  0.127  0.086*  0.144  0.101  0.010*  0.031*  0.008*  0.069* 
adjusted r2  0.256  0.377  0.598  0.371  0.531  0.580  0.670  0.446  0.350 
significance (p value) < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 
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ABBREVIATIONS 
DM1 – myotonic dystrophy type 1 
ePAL – estimated progenitor allele length 
SP-PCR – small pool-PCR 
MIP – maximal inspiratory pressure 
MEP – maximal expiratory pressure 
FVC – forced vital capacity 
PEF – peak expiratory flow 
